Evommune Inc (EVMN) Stock Forecast & Price Target

Evommune is supported by a differentiated two-asset pipeline that targets large, underserved inflammatory markets through EVO756 and EVO301, giving it multiple shots on goal in migraine, atopic dermatitis, and ulcerative colitis. EVO756 has shown proof of mechanism, dose-dependent activity, rapid onset, and clean safety, while emerging PACAP-axis validation and an ongoing Phase 2b migraine study in ~300 refractory patients with topline results expected in 2027 strengthen the case for meaningful commercial potential. EVO301 adds further upside with positive Phase 2a AD data, encouraging PK and tolerability, and a planned Phase 2b start in mid-2027, which together support a credible path to value creation across multi-billion-dollar disease markets.

Evommune is increasingly a single-asset story after EVO756 failed to differentiate from placebo in both CSU and the 121-patient Phase 2b AD study, missing primary and secondary endpoints at every dose and leaving MRGPRX2 with little investable value. The repeated lack of efficacy signals, combined with a competitive AD landscape and unresolved concerns about whether the mechanism can deliver meaningful clinical benefit, weakens confidence in the broader pipeline and limits the chance of near-term commercial relevance. With no revenues and a stated need for additional capital within the next few years, the company also faces meaningful dilution risk while investors wait on unproven IV/SC translation for EVO301 and a migraine readout expected in 2027.